Connect your AI

CorMedix CRMD Total Liabilities & Equity

Total Liabilities & Equity at other companies

PfizerPFE

$207.62B-0.2%

Merck & Co.MRK

$128.69B+11.8%

Merit Medical SystemsMMSI

$2.72B+10.2%

ITG

Integer HoldingsITGR

$3.41B+3.5%

IAR

Integra LifeSciencesIART

$3.58B-11.7%

Emergent BiosolutionsEBS

$1.32B-7.4%

Other financials

Income statement

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CorMedix's total liabilities & equity?: CorMedix (CRMD) reported total liabilities & equity of $815.64M in Q1 2026.
How has CorMedix's total liabilities & equity changed year-over-year?: CorMedix's total liabilities & equity increased by 445.3% year-over-year, from $149.58M to $815.64M.
What is the long-term trend for CorMedix's total liabilities & equity?: Over 5 years (2020 to 2025), CorMedix's total liabilities & equity has grown at a 75.7% compound annual growth rate (CAGR), from $49.31M to $826.14M.
What does total liabilities & equity mean?: Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.